FRIDAY, Feb. 28, 2025 -- Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a...
Vous n'êtes pas connecté
The hormone glucagon-like peptide 1 (GLP-1) is effective in controlling insulin release and reducing appetite. It is marketed as Semaglutide, Ozempic and Wegovy as a diabetes treatment but is better known as a weight loss drug. A recent study by researchers from the University of Palermo found that Semaglutide can also be used to reduce cocaine addiction.Semaglutide was given to a cocaine addict who was using this drug to lose weight. Researchers gave him Semaglutide and after 12 weeks a 12% weight loss was achieved. In addiction tests, the craving for cocaine was reduced by up to 59%.GLP-1 is now a miracle drug with it also being able to reduce alcohol addiction in a study from 2023. But the long-term impact of this drug is still unknown with some of the negative impacts that have been detected including causing a risk of blindness, leaky gut and a reduction in heart muscle.
FRIDAY, Feb. 28, 2025 -- Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a...
MONDAY, Feb. 24, 2025 -- People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye...
FRIDAY, Jan. 14, 2025 -- Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one...
A new study suggests that even modest weight loss with GLP-1 medications like Wegovy and Zepbound can help prevent knee and hip replacements from...
MONDAY, Feb. 24, 2025 -- For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with...
MONDAY, Feb. 24, 2025 (HealthDay news) -- Even slight weight loss spurred on by cutting-edge GLP-1 drugs can help prevent replacement knees and hips...
By Birgitta Dresp-Langley Digital technology and Artificial Intelligence (AI) pose threats to human right to freedom of thought [1], identified in...
TGA approved new indication for semaglutide drug in December 2024, but allocation to PBS still to be decided
Losing weight is a difficult process that takes an equal amount of discipline, commitment, and a well-planned strategy. It entails not just physical...
Discover how semaglutide aids weight loss in individuals with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and its severe form,...